- Home
- XTNT vs ALRN Comparison
XTNT vs ALRN Comparison
Compare XTNT & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- ALRN
- Stock Information
- Founded
- XTNT N/A
- ALRN 2001
- Country
- XTNT United States
- ALRN United States
- Employees
- XTNT N/A
- ALRN N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- ALRN Health Care
- Exchange
- XTNT Nasdaq
- ALRN Nasdaq
- Market Cap
- XTNT 74.1M
- ALRN 76.9M
- IPO Year
- XTNT N/A
- ALRN 2017
- Fundamental
- Price
- XTNT $0.40
- ALRN $2.61
- Analyst Decision
- XTNT Strong Buy
- ALRN Strong Buy
- Analyst Count
- XTNT 1
- ALRN 1
- Target Price
- XTNT $3.00
- ALRN $19.00
- AVG Volume (30 Days)
- XTNT 105.5K
- ALRN 87.4K
- Earning Date
- XTNT 11-12-2024
- ALRN 11-14-2024
- Dividend Yield
- XTNT N/A
- ALRN N/A
- EPS Growth
- XTNT N/A
- ALRN N/A
- EPS
- XTNT N/A
- ALRN N/A
- Revenue
- XTNT $113,862,000.00
- ALRN N/A
- Revenue This Year
- XTNT $31.82
- ALRN N/A
- Revenue Next Year
- XTNT $13.64
- ALRN N/A
- P/E Ratio
- XTNT N/A
- ALRN N/A
- Revenue Growth
- XTNT 45.11
- ALRN N/A
- 52 Week Low
- XTNT $0.39
- ALRN $1.61
- 52 Week High
- XTNT $1.45
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- XTNT 22.17
- ALRN 30.00
- Support Level
- XTNT $0.39
- ALRN $2.50
- Resistance Level
- XTNT $0.54
- ALRN $3.11
- Average True Range (ATR)
- XTNT 0.03
- ALRN 0.37
- MACD
- XTNT -0.01
- ALRN -0.14
- Stochastic Oscillator
- XTNT 12.81
- ALRN 6.35
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.